BioSpace News Archive

The global bioprocess validation market was estimated at USD 295.02 million in 2022 and it is expected to surpass around USD 971.74 million by 2032, poised to grow at a CAGR of 12.66% from 2023 to 2032.

TELA Bio, Inc. today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of stock options to purchase an aggregate of 15,450 shares.

ADMA Biologics, Inc. today announced the closing of its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share.

Arcus Biosciences, Inc. today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 8,200 shares of the Company’s common stock.

Marinus Pharmaceuticals, Inc today announced the grant of inducement awards to two new employees.

Champions Oncology, Inc. will report its financial and operational results for the second quarter ended October 31, 2022, on Tuesday, December 13, 2022, after market close.

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities General Regulation, Innate Pharma SA releases its total number of shares outstanding as well as its voting rights as at December 1, 2022:.

Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter fiscal year 2022 on Thursday, December 15, 2022.

On December 8 , the first Boao International Conference on Real World Studies of Medical Products was held in Hainan Province, with the theme of “Real World Data Studies and Innovative Development and Supervision of Medical Products”.

ImmunoGen, Inc. today announced a clinical collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) to evaluate the safety and anti-leukemia activity of pivekimab sunirine (pivekimab) in combination with magrolimab, a potential, first-in-class, investigational CD47 inhibitor, in patients with relapsed or refractory (R/R) CD123-positive acute myeloid leukemia (AML).